Relativity Healthcare Partners
VC Fund
Relativity Healthcare Partners is a VC fund focused on Medical and Health Care. Relativity Healthcare Partners
- Total investments:
- 9
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Relativity Healthcare Partners invests in
MedicalHealth CareBiotechnologyPharmaceuticalMedical Device
Stages Relativity Healthcare Partners invests in
Series ASeedSeries BSeries DFunding Round
Countries Relativity Healthcare Partners invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Michael Chao
|
|||
4 more contacts available
Investment Focus
Industry
- Medical 5 (56%)
- Health Care 4 (44%)
- Biotechnology 4 (44%)
- Pharmaceutical 3 (33%)
- Medical Device 2 (22%)
Stage
- Series A 4 (44%)
- Seed 2 (22%)
- Series B 1 (11%)
- Series D 1 (11%)
- Funding Round 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Michael Chao
Senior Managing Director
|
Senior Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Anodyne Nanotech
|
Anodyne Nanotech is a preclinical-stage biotech company that develops differentiated, transdermal forms of high-value drugs. Its first practical and cost-effective platform, Hero Patch, delivers clinically meaningful doses of macromolecules such as monoclonal antibodies or small molecules for fast and sustained delivery.The company was founded in2019 by Jake Lombardo, Konstantinos Tzortzakis, and Hojatollah Rezaei Nejad. | $12.6M / Series A / Jun 24, 2026 | |
|
Anodyne Nanotech
|
Anodyne Nanotech is a preclinical-stage biotech company that develops differentiated, transdermal forms of high-value drugs. Its first practical and cost-effective platform, Hero Patch, delivers clinically meaningful doses of macromolecules such as monoclonal antibodies or small molecules for fast and sustained delivery.The company was founded in2019 by Jake Lombardo, Konstantinos Tzortzakis, and Hojatollah Rezaei Nejad. | $4.2M / Seed / May 03, 2021 | |
Burns & Levinson
|
Burns & Levinson is a Boston-based, full service law firm with more than 125 attorneys in Massachusetts, New York and Rhode Island. | $4.2M / Seed / Apr 08, 2021 | |
Earlens
|
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. Thisrevolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum. | $87M / Series D / Oct 22, 2018 | |
OrphoMed
|
OrphoMed is a San Francisco Bay Area pharmaceutical company focused on the development of novel first-in-class therapeutic dimer conjugates based on its proprietary DIMERx™ platform technology. The company is leveraging its DIMERx™ technology to address the problem of visceral hypersensitivity and pancreatitis in the treatment of gastrointestinaldisorders and the unmet medical needs in the treatment of both peripheral neuropathic and systemic nociceptive pain.The lead candidate ORP-101 is a peripherally acting sodium ion channel blocker (Nav 1.7), mu agonist/kappa antagonist dimer. The molecule does not cross the blood brain barrier and, unlike other opioids that constrict the sphincter of Oddi, ORP-101, when given intravenously in animal studies, has instead been shown to relax the sphincter. The former attribute implies no abuse potential and the latter minimizes the risks of pancreatitis and/or abdominal pain related to sphincter of Oddi constriction. These two attributes, in combination with the well-understood pharmacology of ORP-101, make the molecule a suitable candidate for chronic treatment of conditions associated with visceral and somatic hypersensitivity and hyperalgesia. Therefore we have positioned ORP-101 for two non-overlapping indications: the oral form for colonic hyperalgesia and gastric dysmotility in IBS-D and the parenteral form for the treatment of peripheral neuropathic pain. The potential clinical benefits are backed by compelling data from validated animal models.The company is also developing potent non-opioid and opioid conjugates to treat acute and chronic nociceptive pain. The non-opioid analgesic conjugate is designed to be non-ulcerogenic and liver-safe and, therefore, has the potential to reshape the pain market served by acetaminophen and NSAIDs. Similarly, the opioid conjugate is designed to be orally active and have a lower potential for dependence than currently available opioids.DIMERx™ technology results in conjugates designed to preserve the receptor pharmacology of their individual constituents, but to have therapeutic profiles well suited for different clinical indications. The components of the conjugates have all been previously proven to be safe and effective for other indications and, therefore, the conjugates have reduced developmental risks. The DIMERx™ conjugates are considered to be new molecular entities and have composition of matter intellectual property protection. | $39M / Series A / May 24, 2017 | |
LensGen
|
LensGen is an ophthalmic medical device company that has developed a biomimetic, curvature changing fluid-optic intraocular lens designed for the treatment of cataracts and presbyopia. It offers Juvene™ which is designed to fit inside the same location as the natural human lens and adjusts dioptric power on demand through curvature change by usingthe same tiny muscle contractions that occur within the eye. | $21M / Series A / May 01, 2017 | |
TenNor Therapeutics
|
TenNor Therapeutics is a clinical stage, product development company with a sharp focus on unmet medical needs in the area of infectious diseases. The company possesses a dual-acting drug discovery platform with several innovative products in various stages of preclinical and clinical development. The company is developing new drugs for thetreatment of Helicobacter pylori infections, prosthetic joint infections, multidrug-resistant Gram-negative infections and some other common and serious infectious diseases. | $25M / Series B / Sep 19, 2016 | |
BeneStream
|
BeneStream provides medical aid solutions that help employers make choices in complying with the Affordable Care Act. It is a software-as-a-service company providing a low-cost solution to employers facing tough choices under the Affordable Care Act (ACA). New mandates will require large employers to offer costly employer-sponsored insurance (ESI)to their entire full-time workforce – or face fines.BeneStream provides a better choice for employers with a low-income workforce: Outsourced enrollment in Medicaid. This solution will save employers money while complying with ACA and provides them free, comprehensive, and family coverage.In 2014, tens of thousands of employers must offer health insurance to tens of millions of employees for the first time. As a result, employers with more than 50 employees are considering financially tough choices such as offering ACA-compliant insurance to their low-income workforce, offering no insurance – and risk fines, and cut employee hours to part-time.Employers subject to ACA mandates are asking their benefits advisors for a better choice. BeneStream’s technology provides help to eligible low-income employees enroll in the federal Medicaid program. This is a win-win solution because: It saves employers the cost of insurance for their low-income workforce while complying with the ACA; It eliminates the risks of fines for the employer and the employee; and it provides free, comprehensive coverage for the employee and their family, without deductibles or cost-sharing. | $4.3M / Series A / Jul 08, 2015 | |
BioAnalytix
|
Bioanalytix is a pharmaceutically oriented commercial spin out from the Barnett institute of chemical and Biological Analysis at Northeastern university in Boston,MA. Founded by thought leaders in clinical development, regulatory strategy, and advanced analytics,Bioanaytix is working wiht leading Pharmaceutical partners to advance, improve andaccelerate the development and commercialization of biologic and biosimilar drugs. | $3.8M / Oct 24, 2013 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does Relativity Healthcare Partners invest in?
Relativity Healthcare Partners invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Seed stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Relativity Healthcare Partners?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Relativity Healthcare Partners?
The team at Relativity Healthcare Partners includes Michael Chao (Senior Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
